• Explore /
  • Poster
  • / A phase II study of infigratinib in previously treated advanced/metastatic cholangiocarcinoma with <em>FGFR</em> gene fusions/alterations.

A phase II study of infigratinib in previously treated advanced/metastatic cholangiocarcinoma with FGFR gene fusions/alterations.

Abstract Poster

Authors

null

Milind M. Javle

MD Anderson Cancer Center, Houston, TX

Milind M. Javle , Robin Kate Kelley , Christoph Springfeld , Ghassan K. Abou-Alfa , Teresa Macarulla , Suebpong Tanasanvimon , Lipika Goyal , Ivan Borbath , Michael Bitzer , Wei-Peng Yong , Philip Agop Philip , Rafael Alvarez-Gallego , Amit Pande , Stacie Peacock Shepherd , Jacki Fontaine , Sameek Roychowdhury

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Hepatobiliary Cancer

Track

Hepatobiliary Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02150967

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr TPS356)

DOI

10.1200/JCO.2021.39.3_suppl.TPS356

Abstract #

TPS356

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Teresa Macarulla

First Author: Shalini Makawita

Poster

2019 ASCO Annual Meeting

Clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations.

Clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations.

First Author: Alice Boileve

First Author: Milind M. Javle